Shopping Cart 0
Cart Subtotal
USD 0

Bioxyne Ltd (BXN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd (BXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Bioxyne Enters into Agreement with Datapharm Australia 10

Equity Offering 11

Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11

Bioxyne to Raise Funds through Private Placement of Shares 12

Bioxyne Completes Private Placement Of Shares For USD 0.5 Million 13

Debt Offering 14

Bioxyne Announces Private Placement Of Notes For USD 0.5 Million 14

Acquisition 15

Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For USD 1.4 Million 15

Bioxyne Ltd-Key Competitors 16

Bioxyne Ltd-Key Employees 17

Bioxyne Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Financial Announcements 19

Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 19

Corporate Communications 21

May 01, 2018: Bioxyne: Non-Executive Director Appointment-Peter Charles Hughes-Hallett 21

Feb 15, 2018: Bioxyne: Resignation of Director 22

Product News 23

Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 23

Other Significant Developments 24

Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 24

Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 25

Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 26

Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 27

Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Bioxyne Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Bioxyne Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Bioxyne Enters into Agreement with Datapharm Australia 10

Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11

Bioxyne to Raise Funds through Private Placement of Shares 12

Bioxyne Completes Private Placement Of Shares For USD 0.5 Million 13

Bioxyne Announces Private Placement Of Notes For USD 0.5 Million 14

Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For USD 1.4 Million 15

Bioxyne Ltd, Key Competitors 16

Bioxyne Ltd, Key Employees 17

Bioxyne Ltd, Subsidiaries 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Bioxyne Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Bioxyne Ltd (Bioxyne), is a biotechnology company that develops, manufactures, markets and commercializes healthcare products in the areas of immune health and immunotherapeutics. It manufactures consumer food supplements such as, ProTract and Progastrim, which are based on a proprietary probiotic strain PCC (lactobacillus fermentum). It also develops a range of existing functional food and beauty products containing ingredients sourced from New Zealand. The company caters to consumer dietary supplements and functional foods markets. Its products are used as dietary supplement and foodstuffs and beverages. The company has manufacturing and distribution agreements with Chr. Hansen and Nu-Skin Enterprises. The company distributes its products across North America and Europe. Bioxyne is headquartered in Sydney, New South Wales, Australia.

Bioxyne Ltd (BXN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deal Details 10

Partnerships 10

Bioxyne Enters into Agreement with Datapharm Australia 10

Equity Offering 11

Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11

Bioxyne to Raise Funds through Private Placement of Shares 12

Bioxyne Completes Private Placement Of Shares For USD 0.5 Million 13

Debt Offering 14

Bioxyne Announces Private Placement Of Notes For USD 0.5 Million 14

Acquisition 15

Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For USD 1.4 Million 15

Bioxyne Ltd-Key Competitors 16

Bioxyne Ltd-Key Employees 17

Bioxyne Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Financial Announcements 19

Feb 27, 2017: Bioxyne: Interim Financial Report For the Half Year ended 31 December 2016 19

Corporate Communications 21

May 01, 2018: Bioxyne: Non-Executive Director Appointment-Peter Charles Hughes-Hallett 21

Feb 15, 2018: Bioxyne: Resignation of Director 22

Product News 23

Dec 11, 2017: Positive Bioxyne Gut Health Clinical Trial Results 23

Other Significant Developments 24

Oct 29, 2018: Bioxyne: Quarterly report for the period ended 30 September 2018 24

Jul 27, 2018: Bioxyne: Quarterly report for the period ended 30 June 2018 25

Apr 27, 2018: Bioxyne: Quarterly Report for the Period ended 31 March 2018 26

Jul 31, 2017: Bioxyne: Quarterly Report for the Period Ended 30 June 2017 27

Apr 27, 2017: Bioxyne: Quarterly Report for the Period Ended 31 March 2017 28

Appendix 29

Methodology 29

About GlobalData 29

Contact Us 29

Disclaimer 29


List Of Figure

List of Figures

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Bioxyne Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Bioxyne Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Bioxyne Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

Bioxyne Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Bioxyne Enters into Agreement with Datapharm Australia 10

Bioxyne Raises USD1.9 Million in Underwritten Non-Renounceable Right Issue 11

Bioxyne to Raise Funds through Private Placement of Shares 12

Bioxyne Completes Private Placement Of Shares For USD 0.5 Million 13

Bioxyne Announces Private Placement Of Notes For USD 0.5 Million 14

Mariposa Health Completes Acquisition Of Hunter Immunology From Bioxyne For USD 1.4 Million 15

Bioxyne Ltd, Key Competitors 16

Bioxyne Ltd, Key Employees 17

Bioxyne Ltd, Subsidiaries 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Bioxyne Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.